Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02141711
Other study ID # TAK-438_107
Secondary ID U1111-1153-84432
Status Completed
Phase Phase 1
First received May 15, 2014
Last updated May 15, 2014
Start date October 2008
Est. completion date February 2009

Study information

Verified date May 2014
Source Takeda
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel, multiple-dose schedule.


Description:

The drug being tested in this study is called TAK-438. TAK-438 is being tested to find a safe and well-tolerated dose. This study looked at pharmacokinetic (effect of the body on the drug) and pharmacodynamic properties (effect of the drug on the body) as well as look at lab results and side effects in people who took TAK-438. This study was designed as a randomized, sequential-panel, multiple repeat dose study.

The study population consisted of 4 Cohorts with 12 participants in each Cohort; with 9 participants randomized to receive a single dose of TAK-438, and 3 participants to receive placebo. Participants in each Cohort received a single dose of study drug once daily after a 10-hour fast. The starting dose was 10 mg followed by administrations of 20, 40, and 30 mg.

This single-centre trial was conducted in the United Kingdom. The overall time to participate in this study was up to 37 days. Participants made 2 visits to the clinic for screening, one 11-day period of confinement to the clinic, and 2 further visits after the confinement period. All participants were contacted by telephone 7 days after last dose of study drug for a follow-up assessment.


Other known NCT identifiers
  • NCT01873209

Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date February 2009
Est. primary completion date February 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Male subjects aged 18 to 45, inclusive, who are in good health, as determined by medical history, physical examination, clinical laboratory evaluations and urine drug screen.

- The subject has the ability to tolerate the pH probe for 24 hours prior to Randomization (Day 1).

Exclusion Criteria:

- Clinically significant history of hypersensitivity to any drug or food or any excipients of TAK-438

- History of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive esophagitis, duodenal ulcer,gastric ulcer, dyspepsia, Barrett's esophagus, or Zollinger-Ellison syndrome

- The subject has a positive test result for Helicobacter pylori at the Initial Screening Visit

- Any clinically significant results from physical examinations or clinical laboratory results as deemed by the investigator.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Intervention

Drug:
TAK-438
TAK-438 tablets
TAK-438 Placebo
TAK-438 placebo-matching tablets

Locations

Country Name City State
United Kingdom Hammersmith Medicines Research London

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul (AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC[0-tlqc]). Days 1 and 7 No
Primary AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity. Days 1 and 7 No
Primary AUC(0-tau): Area Under the Plasma Concentration-time Curve from Time 0 to Time tau Over the Dosing Interval for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul AUC(0-tau) is a measure of the area under the plasma concentration-time curve from time 0 to time tau over a dosing interval, where tau is the length of the dosing interval. Days 1 and 7 No
Primary Cmax: Maximum Observed Plasma Concentration for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Days 1 and 7 No
Primary Cmin,ss: Minimum Observed Plasma Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Day 7 No
Primary Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Day 7 No
Primary (Cmax-Cmin)/Cavg: Fluctuation of Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul (Cmax-Cmin)/Cavg, where Cmin is the minimum observed plasma concentration and Cavg is the average plasma concentration at steady state. Day 7 No
Primary Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax. Days 1 and 7 No
Primary Terminal Elimination Rate Constant (?z) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Terminal elimination rate constant (?z) is the rate at which drugs are eliminated from the body. Days 1 and 7 No
Primary Terminal Elimination Half-life (T1/2) Pharmacokinetic Parameter for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma. Days 1 and 7 No
Primary Apparent Clearance (CL/F) Pharmacokinetic Parameter for TAK-438 CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-24), expressed in L/hr. Days 1 and 7 No
Primary Apparent Volume of Distribution (Vz/F) for TAK-438 Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by ?z. Days 1 and 7 No
Primary Ae(0-t): Total Amount of Drug Excreted in Urine from Time 0 to Time T for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Ae(0-t) is the total amount of drug excreted in urine from time 0 to t, where t is 24 hours on Day 1 and 48 hours on Day 7. Day 1 and Day 7 No
Primary Ae(0-tau): Total Amount of Drug Excreted in Urine from Time 0 to Time tau for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Ae(0-tau) is the total amount of drug excreted in urine from time 0 to tau, where tau equals 24 hours. Day 1 and Day 7 No
Primary Renal Clearance (CLr) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul CLr is a measure of apparent clearance of the drug from the urine calculated as total amount excreted in the urine from time 0 to 24 hours postdose / plasma area under the curve from time 0 to 24 hours post-dose. Day 1 and Day 7 No
Primary Fraction of TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Excreted in Urine (Fe) Fe is a measure of the fraction of drug excreted in urine and is calculated as Fe = (total amount excreted in the urine from time 0 to 24 hours post-dose / dose)×100. Day 1 and Day 7 No
Primary Physical Examination Findings A baseline physical examination (defined as the pretreatment assessment immediately prior to the start of study drug) will consist of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; (11) genitourinary system; and (12) other. All subsequent physical examinations should assess clinically significant changes from the baseline examination. Baseline up to Day 9 Yes
Primary Number of Participants With Potentially Clinically Significant Vital Sign Findings Participants with at least one potentially clinically significant post-baseline vital sign finding. Vital signs will include body temperature (oral temperature), sitting blood pressure (after sitting for 5 minutes), and pulse (bpm). Baseline up to Day 9 Yes
Primary Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings Full 12-lead ECGs will be recorded using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (using Bazett correction; QTcB) intervals. The investigator or other qualified physician will interpret each ECG using one of the following categories: within normal limits, abnormal but not clinically significant, or abnormal and clinically significant. Baseline to Day 9 Yes
Primary Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings Laboratory tests for hematology, serum chemistries, coagulation tests, and urinalysis will be performed. Baseline up to Day 9 Yes
Primary Number of Participants With Treatment-Emergent Adverse Events (AEs) Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 7 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug. Baseline up to Day 9 Yes
Primary Safety of TAK-438 Assessed by physical examination, ECG, and safety tests of blood/urine 3 months Yes
Primary Tolerability of TAK-438 Assessed by adverse events 3 months Yes
Primary Pharmacokinetic analysis of plasma TAK-438 concentrations Primary pharmacokinetic parameters (AUC (0-tlqc), AUC (0-inf), Cmax) for TAK-438 and its metabolites M-I, M-II, M-III and M-IV-Sul will be subject to statistical analysis 3 months Yes
Primary Pharmacodynamic measurement for assay of gastric pH, measurement of gastrin, pepsinogen I, pepsinogen II and the pepsinogen I/II ratio in plasma samples 3 months Yes
Secondary Percentage of Time the pH is Greater than pH 4 and pH 5 over a 24 Hour Period Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 24-hour period at Baseline and over a 24-hour period following the administration of study on Days 1, 4 and 7. Over a 24-hour period at Baseline and over a 24-hour period following the administration of study on Days 1, 4 and 7 No
Secondary Percentage of Time the pH is Greater than pH 4 and pH 5 over a 48 Hour Period Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 48-hour period following the administration of study drug on Day 7. Over a 48-hour period following the administration of study on Day 7 No
Secondary Percentage of Time the PH is Greater than pH 4 and pH 5 from 8 PM to 8 AM Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 12-hour period from 8 PM to 8 AM to assess nocturnal pH. Over a 12-hour period from 8 PM to 8 AM on Days 1, 4 and 7 No
Secondary Total Amount of Gastrin in Plasma Predose Days 1 through 7 and Days 8 and 9 No
Secondary Total Amount of Pepsinogen I in Plasma Predose Days 1 through 7 and Days 8 and 9 No
Secondary Total Amount of Pepsinogen II in Plasma Predose Days 1 through 7 and Days 8 and 9 No
Secondary Pepsinogen I/II Ratio in Plasma Predose Days 1 through 7 and Days 8 and 9 No
See also
  Status Clinical Trial Phase
Completed NCT03561883 - Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) Phase 3
Completed NCT01406210 - RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol N/A
Completed NCT02555852 - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia N/A
Terminated NCT01327963 - Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study N/A
Completed NCT01570842 - Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury N/A
Terminated NCT00587275 - Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI Phase 2
Completed NCT00228527 - Esomeprazole for Treatment of GERD in Pediatric Patients Phase 4
Completed NCT00261300 - Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708) Phase 3
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Completed NCT00795093 - Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US N/A
Completed NCT00394472 - Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients Phase 2
Completed NCT00574925 - Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Phase 4
Terminated NCT02749071 - An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux N/A
Recruiting NCT01129713 - Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE. Phase 1/Phase 2
Completed NCT00734747 - Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD) Phase 3
Completed NCT00312806 - Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341) Phase 3
Not yet recruiting NCT05579587 - Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
Recruiting NCT02366169 - Medigus Ultrasonic Surgical Endostapler (MUSE) Registry N/A
Completed NCT01374074 - Racial Disparity in Barrett's Esophagus N/A
Terminated NCT00857597 - Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment Phase 3